Acta Scientific Pharmaceutical Sciences (ISSN: 2581-883X)

Review Article Volume 4 Issue 6

Novel COVID-19 Treatment with Novel Therapy

Javeria Fazal*

Department of Clinical Pharmacy, University of Calabria, Italy

*Corresponding Author: Javeria Fazal, Department of Clinical Pharmacy, University of Calabria, Italy.

Received: March 30, 2020; Published: May 11, 2020


The main purpose of this research is to laid down a new concept so to save lives of corona infected patients. As coronavirus is spreading widely in all over the world and many deaths have been reported due to this life threatening disease. So in this study, a new strategy has been introduced for the very old vitamin D in order to put forward that how vitamin D can be used as a primary precursor for the treatment of novel coronavirus as vitamin D is very important in boosting immune system.





Citation: Javeria Fazal. “Novel COVID-19 Treatment with Novel Therapy”.Acta Scientific Pharmaceutical Sciences 4.6 (2020): 13.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US